Results 121 to 130 of about 1,044,115 (187)

Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer. [PDF]

Clin Mol Hepatol
Li S, Shan Y, Chen T, Topatana W, Juengpanich S, Lu Z, Sun Y, Xie T, Ruijing R, Hou L, Chen J, Chen G, Lv J, Ma X, Guo P, Duda DG, Cai X, Chen M.   +17 more
europepmc   +1 more source

Synthetic lethality of mRNA quality control complexes in cancer

Synthetic lethality exploits the genetic vulnerabilities of cancer cells to enable a targeted, precision approach to treat cancer1. Over the past 15 years, synthetic lethal cancer target discovery approaches have led to clinical successes of PARP ...
Deborah Widomski, Kaitlin Kentala, Vlasios Manaves, Joshua P. Plotnik, Charles Lu, Vivian Prindle, Stephanie Sandoval, Maricel Torrent, Sakina Petiwala, Phuong Le, William N. Pappano, Marianne B. Palczewski, Zoltan Dezso, Jonathan A. Meulbroek, Daniel Verduzco, F. Gregory Buchanan, Dong Cheng, Kimberly R. Sher, Adam E. Richardson, Diya Mitra, Anlu Chen, Sarah Kongpachith, Stephen Walker, Xu Shi, Brian Bierie   +24 more
core  

Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies. [PDF]

J Cell Mol Med
Wu L, Deng Y, Lei Z, Wang Y, Huang S.
europepmc   +1 more source

A Synthetic Lethality-Informed Multi-Omic Framework for Identifying a Five-Gene Diagnostic Signature in Chronic Obstructive Pulmonary Disease. [PDF]

Curr Issues Mol Biol
Yang Y, Wang Z, Su X, Tang J, Zhang Z, Fan X, Xu H, Wang L, Luo Z.   +8 more
europepmc   +1 more source

PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity. [PDF]

Sci Adv
Liu Y, Jiang M, Ding M, Ullah I, Wang H, Xie W, Wang K, Yuan Y.   +7 more
europepmc   +1 more source

Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers. [PDF]

Ther Adv Med Oncol
Lebeau A, Kakkos A, Leroi N, Bours V, Delbecque K, Goffin F, Gonne E, Gennigens C.   +7 more
europepmc   +1 more source

Inhibition of PRMT5 triggers synthetic lethality in ARID1A-deficient endometrial cancer by promoting aberrant R-loop accumulation. [PDF]

Mol Cancer
Shu W, Dong K, Shen X, Zhou X, Zhang J, Yu S, Cheng S, Zhang T, Chen G, Zhong G, Zhang J, Wang H.   +11 more
europepmc   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance. [PDF]

Clin Transl Med
Li J, Zhang L, Shang Y, Liu J, Zhao H.
europepmc   +1 more source

Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade. [PDF]

Proc Natl Acad Sci U S A
Abt ER, Wang L, Varuzhanyan G, Freeland J, He T, Peña-Garcia GM, Ruegg L, McLaughlin J, Cheng D, Balanis NG, Chen CC, Xu Y, Xing Y, Memarzadeh S, Radu CG, Graeber TG, Witte ON.   +16 more
europepmc   +1 more source

Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair. [PDF]

Mol Cancer
Bigdeli M, Tremblay E, Provencher D, Mes-Masson AM, Rodier F.   +4 more
europepmc   +1 more source